S Ritland

1.3k total citations
22 papers, 965 citations indexed

About

S Ritland is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, S Ritland has authored 22 papers receiving a total of 965 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Molecular Biology and 6 papers in Genetics. Recurrent topics in S Ritland's work include Cancer-related Molecular Pathways (4 papers), Cancer Genomics and Diagnostics (4 papers) and Hemoglobinopathies and Related Disorders (4 papers). S Ritland is often cited by papers focused on Cancer-related Molecular Pathways (4 papers), Cancer Genomics and Diagnostics (4 papers) and Hemoglobinopathies and Related Disorders (4 papers). S Ritland collaborates with scholars based in United States, Switzerland and Canada. S Ritland's co-authors include Robert B. Jenkins, Sandra Gendler, Lynn C. Hartmann, William A. Cliby, Karl C. Podratz, Gary L. Keeney, Richard J. Dahl, Kevin C. Halling, Mark Dodson and Bernd W. Scheithauer and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

S Ritland

20 papers receiving 943 citations

Peers

S Ritland

ONCOL

PFM

GENET

Barbara Quaresima Italy

Robin L. Goode United States

Samuel Seoane Spain

Briony E. Cristiano Australia

Karen G. Montgomery Australia

Louis Hornez France

Shiro Koizume Japan

Chiyomi Egawa Japan

Weiguo Wu United States

Kirsi Syrjäkoski Finland

Barbara Quaresima Italy

S Ritland

653 ×1.5

338 ×1.4

313 ×1.3

ONCOL

188 ×0.8

PFM

256 ×1.2

GENET

Citations per year, relative to S Ritland S Ritland (= 1×) peers Barbara Quaresima

Countries citing papers authored by S Ritland

Since Specialization

Citations

This map shows the geographic impact of S Ritland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S Ritland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S Ritland more than expected).

Fields of papers citing papers by S Ritland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S Ritland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S Ritland. The network helps show where S Ritland may publish in the future.

Co-authorship network of co-authors of S Ritland

This figure shows the co-authorship network connecting the top 25 collaborators of S Ritland. A scholar is included among the top collaborators of S Ritland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S Ritland. S Ritland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Nianhang, Nastya Kassir, Abderrahmane Laadem, et al.. (2020). Population Pharmacokinetics and Exposure–Response of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With Myelodysplastic Syndromes. CPT Pharmacometrics & Systems Pharmacology. 9(7). 395–404. 6 indexed citations

Chen, Nianhang, Abderrahmane Laadem, Dawn Wilson, et al.. (2016). Pharmacokinetics and Exposure-Response of Luspatercept in Patients with Beta-Thalassemia: Preliminary Results from Phase 2 Studies. Blood. 128(22). 2463–2463. 8 indexed citations

Luistro, Leopoldo, James Rosinski, Hongjin Bian, et al.. (2012). Development and characterization of a preclinical ovarian carcinoma model to investigate the mechanism of acquired resistance to trastuzumab. International Journal of Oncology. 41(2). 639–651. 7 indexed citations

Berkofsky‐Fessler, Windy, Paul Delmar, Juliette Molnos, et al.. (2009). Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients. Molecular Cancer Therapeutics. 8(9). 2517–2525. 18 indexed citations

Pappo, Alberto S., J. Crowley, Denise K. Reinke, et al.. (2009). A SARC global collaborative phase II trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R) in patients with recurrent or refractory sarcomas. Journal of Clinical Oncology. 27(15_suppl). 10503–10503. 28 indexed citations

Luistro, Leopoldo, James Rosinski, Hongjin Bian, Nicholas M. Ponzio, & S Ritland. (2005). Herceptin-refractory ovarian carcinoma cells differentially express genes involved in angiogenesis, invasion, and metastasis. Cancer Research. 65. 1201–1201. 1 indexed citations

Luistro, Leopoldo, Christian Tovar, Subal Bishayee, et al.. (2004). Development and characterization of a pre-clinical model of ovarian carcinoma to investigate mechanisms of resistance to the anti-HER2/neu antibody Herceptin™. Cancer Research. 64. 276–276. 1 indexed citations

Salazar, Ramón, Donald Bissett, Chris Twelves, et al.. (2004). A Phase I Clinical and Pharmacokinetic Study of Ro 31-7453 Given as a 7- or 14-Day Oral Twice Daily Schedule Every 4 Weeks in Patients with Solid Tumors. Clinical Cancer Research. 10(13). 4374–4382. 6 indexed citations

Ritland, S & Sandra Gendler. (1999). Chemoprevention of intestinal adenomas in the ApcMin mouse by piroxicam: kinetics, strain effects and resistance to chemosuppression. Carcinogenesis. 20(1). 51–58. 86 indexed citations

10.

Ritland, S, Jonathan A. Leighton, Rhoda Elison Hirsch, et al.. (1999). Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse.. PubMed. 5(4). 855–63. 38 indexed citations

11.

Rowse, Gerald J., S Ritland, & Sandra Gendler. (1998). Genetic modulation of neu proto-oncogene-induced mammary tumorigenesis.. PubMed. 58(12). 2675–9. 45 indexed citations

12.

Takahashi, Satoru, Ailin Shan, S Ritland, et al.. (1995). Frequent loss of heterozygosity at 7q31.1 in primary prostate cancer is associated with tumor aggressiveness and progression.. PubMed. 55(18). 4114–9. 100 indexed citations

13.

Tomlinson, Francis H., Robert B. Jenkins, Bernd W. Scheithauer, et al.. (1994). Aggressive Medulloblastoma With High-Level N-myc Amplification. Mayo Clinic Proceedings. 69(4). 359–365. 41 indexed citations

14.

Cliby, William A., S Ritland, Lynn C. Hartmann, et al.. (1993). Human epithelial ovarian cancer allelotype.. PubMed. 53(10 Suppl). 2393–8. 215 indexed citations

15.

Dodson, Mark K., Lynn C. Hartmann, William A. Cliby, et al.. (1993). Comparison of loss of heterozygosity patterns in invasive low-grade and high-grade epithelial ovarian carcinomas.. PubMed. 53(19). 4456–60. 86 indexed citations

16.

Ransom, David, S Ritland, David W. Kimmel, et al.. (1992). Cytogenetic and loss of heterozygosity studies in ependymomas, pilocytic astrocytomas, and oligodendrogliomas. Genes Chromosomes and Cancer. 5(4). 348–356. 150 indexed citations

17.

Herrmann, Marie A., Ian Hay, S Ritland, et al.. (1991). Cytogenetic and molecular genetic studies of follicular and papillary thyroid cancers.. Journal of Clinical Investigation. 88(5). 1596–1604. 107 indexed citations

18.

Peterson, Donald I., et al.. (1979). The fortune of a capacious spinal canal.. PubMed. 71(10). 985–7. 5 indexed citations

19.

Ritland, S. (1968). [Stevens-Johnson syndrome after treatment with Tanderil].. PubMed. 88(21). 2021–2. 2 indexed citations

20.

Ritland, S. (1967). Hemolytic Anemia in Wilson's Disease. New England Journal of Medicine. 276(8). 475–475.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact